Synced daily from ClinicalTrials.gov via AACT. Last sync: .
20 Iptacopan clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 18 indications (including Atypical Hemolytic Uremic Syndrome & Paroxysmal Nocturnal Hemoglobinuria) and 1,602 total planned enrollment. 9 Phase 3 Iptacopan trials and 6 Phase 2 are listed. 9 Iptacopan clinical trials are actively recruiting at 68 U.S. sites across 29 states. Most recent activity: NCT06517758 (May 2032).
Where to Participate: All Iptacopan Trial Sites in the U.S. (68 sites across 29 states)
Every actively recruiting Iptacopantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.
20 Iptacopan clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 5 are marked completed.
Are Iptacopan clinical trials recruiting in 2026?
Yes — 7 Iptacopan trials are actively recruiting in 2026, with 68 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Iptacopan being studied for?
Iptacopan is being studied for Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis, C3 Glomerulopathy (C3G) and 17 more. The trials are grouped by indication on this page.
What phase is Iptacopan in?
Iptacopan clinical trials span 9 Phase 3, 6 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Iptacopan clinical trials?
The lead sponsor across the most Iptacopan trials is Novartis Pharmaceuticals, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Iptacopanas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.